Product
RegeneCyte
1 clinical trial
3 indications
Indication
Long COVIDIndication
Post-COVID SyndromeIndication
Post COVID-19 ConditionClinical trial
A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID SyndromeStatus: Recruiting, Estimated PCD: 2024-10-01